Supplementary Materials for
Consolidated Financial Results for
the 3rd Quarter of Fiscal Year 2022. 12 (IFRS)
Chugai Pharmaceutical co., ltd.
Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
- Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
- Exchange rates used for each period are as follows.
QTR | (Yen) | |||||||||||
Actual* | Actual* | |||||||||||
FY2021 | FY2022 | |||||||||||
1-3 | 4-6 | 7-9 | 10-12 | 1-3 | 4-6 | 7-9 | 10-12 | |||||
QTR | QTR | QTR | QTR | QTR | QTR | QTR | QTR | |||||
CHF | 117.08 | 120.11 | 119.88 | 123.26 | 125.78 | 134.34 | 143.10 | |||||
EUR | 127.65 | 131.87 | 129.78 | 130.02 | 130.43 | 138.07 | 139.33 | |||||
USD | 105.83 | 109.44 | 110.08 | 113.66 | 116.17 | 129.58 | 138.28 | |||||
SGD | 79.47 | 82.12 | 81.39 | 83.75 | 85.92 | 94.09 | 98.96 | |||||
*Market average exchange rate | ||||||||||||
YTD | ||||||||||||
Actual* | Actual* | Actual* | Assumption | |||||||||
FY2020 | FY2021 | FY2022 | FY2022 | |||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-12 | |||
Full-year | YTD | YTD | YTD | Full-year | YTD | YTD | YTD | Full-year | Full-year | |||
CHF | 113.72 | 117.08 | 118.60 | 119.03 | 120.10 | 125.78 | 130.15 | 134.54 | 122.00 | |||
EUR | 121.69 | 127.65 | 129.76 | 129.77 | 129.83 | 130.43 | 134.35 | 136.10 | 130.00 | |||
USD | 106.80 | 105.83 | 107.63 | 108.45 | 109.75 | 116.17 | 122.87 | 128.01 | 112.00 | |||
SGD | 77.41 | 79.47 | 80.80 | 81.00 | 81.69 | 85.92 | 90.04 | 93.07 | 84.00 | |||
*Market average exchange rate | ||||||||||||
Period-end | ||||||||||||
Actual | Actual | Actual | ||||||||||
FY2020 | FY2021 | FY2022 | ||||||||||
31 Dec. | 31 Mar. | 30 Jun. | 30 Sep. | 31 Dec. | 31 Mar. | 30 Jun. | 30 Sep. | 31 Dec. | ||||
CHF | 117.10 | 117.14 | 120.02 | 119.76 | 125.95 | 131.93 | 142.99 | 148.07 | ||||
EUR | 126.89 | 129.30 | 131.48 | 129.85 | 130.31 | 135.92 | 142.62 | 141.81 | ||||
USD | 103.19 | 110.37 | 110.52 | 111.97 | 115.07 | 121.82 | 136.60 | 144.47 | ||||
SGD | 77.98 | 81.87 | 82.15 | 82.27 | 85.09 | 90.07 | 98.01 | 100.83 |
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 3rd quarter of FY2022(IFRS) | 1 |
Reconciliation of IFRS results to Core results
(Billions of yen) | |||||||||||
FY2021 | FY2022 | ||||||||||
1-9 | 1-9 | ||||||||||
IFRS results | Intangible | Others | Core results | IFRS results | Intangible | Others | Core results | ||||
assets | assets | ||||||||||
Revenues | 677.5 | - | - | 677.5 | 821.5 | - | (91.9) | 729.5 | |||
Sales | 538.7 | - | - | 538.7 | 644.7 | - | - | 644.7 | |||
Royalties and other operating income | 138.8 | - | - | 138.8 | 84.9 | - | - | 84.9 | |||
Other revenue | - | - | - | - | 91.9 | - | (91.9) | - | |||
Cost of sales | (227.6) | 1.9 | - | (225.7) | (263.3) | 0.9 | - | (262.4) | |||
Gross profit | 449.9 | 1.9 | - | 451.8 | 558.1 | 0.9 | (91.9) | 467.1 | |||
Operatingexpenses | (167.1) | 2.7 | 3.3 | (161.1) | (174.3) | 0.5 | 5.7 | (168.1) | |||
Marketing and distribution | (52.2) | - | 0.0 | (52.2) | (54.1) | - | 0.2 | (53.9) | |||
Research and development | (99.5) | 2.7 | 2.7 | (94.1) | (104.4) | 0.5 | 2.9 | (101.0) | |||
General and administration | (15.3) | - | 0.6 | (14.7) | (15.8) | - | 2.6 | (13.2) | |||
Operating profit | 282.8 | 4.6 | 3.3 | 290.7 | 383.8 | 1.4 | (86.2) | 299.0 | |||
Financing costs | (0.0) | - | - | (0.0) | (0.0) | - | - | (0.0) | |||
Other financial income (expense) | 0.9 | - | - | 0.9 | 0.6 | - | - | 0.6 | |||
Other expense | (2.8) | - | - | (2.8) | (2.4) | - | - | (2.4) | |||
Profitbefore taxes | 280.9 | 4.6 | 3.3 | 288.9 | 382.0 | 1.4 | (86.2) | 297.1 | |||
Income taxes | (76.8) | (1.4) | (1.0) | (79.2) | (110.0) | (0.4) | 26.3 | (84.1) | |||
Net income | 204.2 | 3.2 | 2.3 | 209.7 | 272.0 | 1.0 | (59.9) | 213.0 | |||
Attributable to | |||||||||||
Chugai shareholders | 204.2 | 3.2 | 2.3 | 209.7 | 272.0 | 1.0 | (59.9) | 213.0 | |||
Non-controlling interests | - | - | - | - | - | - | - | - |
Core results
Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results. Chugai's recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.
The table above shows the reconciliation of IFRS results into Core results. The detail is as below.
Intangible assets
Amortization (1.9 billion yen in 2021 and 1.1 billion yen in 2022)
Impairment (2.7 billion yen in 2021 and 0.3 billion in 2022)
Others
Lump sum income related to settlement agreement etc.(None in 2021 and -90.7 billion yen in 2022) Restructuring expenses etc. (3.3 billion yen in 2021 and 4.5 billion yen in 2022)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 3rd quarter of FY2022(IFRS) | 2 | |||||||||||||||||
IFRS results (QTR) | ||||||||||||||||||
3 | 4 | 5 | 6 | (Billions of yen) | ||||||||||||||
Actual | Actual | |||||||||||||||||
FY2021 | FY2022 | |||||||||||||||||
1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change | 4-6 | Change | 7-9 | Change | 10-12 | Change | |||||||
QTR | QTR | QTR | QTR | QTR | (%) | QTR | (%) | QTR | (%) | QTR | (%) | |||||||
Revenues | 168.8 | 221.4 | 287.3 | 322.3 | 360.6 | +113.6 | 235.6 | +6.4 | 225.3 | (21.6) | ||||||||
Sales | 130.3 | 173.9 | 234.5 | 264.1 | 242.7 | +86.3 | 210.1 | +20.8 | 191.9 | (18.2) | ||||||||
Domestic | 94.9 | 108.5 | 159.2 | 156.3 | 161.7 | +70.4 | 112.1 | +3.3 | 113.7 | (28.6) | ||||||||
Overseas | 35.4 | 65.3 | 75.3 | 107.8 | 81.0 | +128.8 | 98.0 | +50.1 | 78.1 | +3.7 | ||||||||
Royalties and other operating income | 38.6 | 47.5 | 52.7 | 58.1 | 25.9 | (32.9) | 25.5 | (46.3) | 33.4 | (36.6) | ||||||||
Royalty and profit-sharing income | 36.6 | 46.7 | 52.1 | 51.8 | 25.2 | (31.1) | 25.2 | (46.0) | 30.3 | (41.8) | ||||||||
Other operating income | 2.0 | 0.8 | 0.6 | 6.4 | 0.7 | (65.0) | 0.3 | (62.5) | 3.1 | +416.7 | ||||||||
Other revenue | - | - | - | - | 91.9 | - | - | - | - | - | ||||||||
Cost of sales | (55.3) | (68.1) | (104.2) | (110.6) | (114.4) | +106.9 | (79.8) | +17.2 | (69.1) | (33.7) | ||||||||
(% of Sales) | 42.4 | 39.2 | 44.4 | 41.9 | 47.1 | - | 38.0 | - | 36.0 | - | ||||||||
Gross profit | 113.5 | 153.4 | 183.1 | 211.7 | 246.1 | +116.8 | 155.8 | +1.6 | 156.2 | (14.7) | ||||||||
(% of Revenues) | 67.2 | 69.3 | 63.7 | 65.7 | 68.2 | - | 66.1 | - | 69.3 | - | ||||||||
Operating expenses | (49.5) | (56.6) | (60.9) | (72.6) | (59.1) | +19.4 | (55.8) | (1.4) | (59.3) | (2.6) | ||||||||
(% of Revenues) | 29.3 | 25.6 | 21.2 | 22.5 | 16.4 | - | 23.7 | - | 26.3 | - | ||||||||
Marketing and distribution | (15.9) | (17.9) | (18.5) | (24.3) | (16.8) | +5.7 | (18.5) | +3.4 | (18.8) | +1.6 | ||||||||
(% of Revenues) | 9.4 | 8.1 | 6.4 | 7.5 | 4.7 | - | 7.9 | - | 8.3 | - | ||||||||
Research and development | (29.7) | (33.6) | (36.2) | (37.8) | (33.9) | +14.1 | (33.8) | +0.6 | (36.7) | +1.4 | ||||||||
(% of Revenues) | 17.6 | 15.2 | 12.6 | 11.7 | 9.4 | - | 14.3 | - | 16.3 | - | ||||||||
General and administration | (3.9) | (5.2) | (6.3) | (10.5) | (8.5) | +117.9 | (3.5) | (32.7) | (3.8) | (39.7) | ||||||||
(% of Revenues) | 2.3 | 2.3 | 2.2 | 3.3 | 2.4 | - | 1.5 | - | 1.7 | - | ||||||||
Operating profit | 64.0 | 96.7 | 122.2 | 139.1 | 187.0 | +192.2 | 99.9 | +3.3 | 96.9 | (20.7) | ||||||||
(% of Revenues) | 37.9 | 43.7 | 42.5 | 43.2 | 51.9 | - | 42.4 | - | 43.0 | - | ||||||||
Financing costs | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | 0.0 | (0.0) | 0.0 | (0.0) | 0.0 | ||||||||
Other financial income (expense) | 0.3 | 0.3 | 0.3 | (0.9) | 1.6 | +433.3 | 0.8 | +166.7 | (1.8) | - | ||||||||
Other expense | - | (0.0) | (2.8) | 0.3 | (2.4) | - | - | - | - | - | ||||||||
Profit before taxes | 64.2 | 97.0 | 119.7 | 138.4 | 186.2 | +190.0 | 100.7 | +3.8 | 95.0 | (20.6) | ||||||||
(% of Revenues) | 38.0 | 43.8 | 41.7 | 42.9 | 51.6 | - | 42.7 | - | 42.2 | - | ||||||||
Income taxes | (16.8) | (26.3) | (33.7) | (39.6) | (54.4) | +223.8 | (28.3) | +7.6 | (27.2) | (19.3) | ||||||||
Net income | 47.4 | 70.7 | 86.0 | 98.8 | 131.8 | +178.1 | 72.4 | +2.4 | 67.8 | (21.2) | ||||||||
(% of Revenues) | 28.1 | 31.9 | 29.9 | 30.7 | 36.6 | - | 30.7 | - | 30.1 | - | ||||||||
Attributable to | ||||||||||||||||||
Chugai shareholders | 47.4 | 70.7 | 86.0 | 98.8 | 131.8 | +178.1 | 72.4 | +2.4 | 67.8 | (21.2) | ||||||||
Non-controlling interests | - | - | - | - | - | - | - | - | - | - | ||||||||
Earnings per share | ||||||||||||||||||
Basic (yen) | 28.84 | 43.02 | 52.31 | 60.11 | 80.14 | +177.9 | 44.00 | +2.3 | 41.21 | (21.2) | ||||||||
Diluted (yen) | 28.82 | 42.99 | 52.28 | 60.08 | 80.09 | +177.9 | 43.99 | +2.3 | 41.20 | (21.2) |
Other financial income (expense) includes net amount of FX related gains/losses.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 3rd quarter of FY2022(IFRS) | 3 | ||||||||||||||||||
IFRS results (YTD) | |||||||||||||||||||
2 | 3 | (Billions of yen) | |||||||||||||||||
Actual | Actual | Actual | |||||||||||||||||
FY2020 | FY2021 | FY2022 | |||||||||||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change | 1-6 | Change | 1-9 | Change | 1-12 | Change | |||||||
YTD | YTD | YTD | YTD | YTD | YTD | (%) | YTD | (%) | YTD | (%) | YTD | (%) | |||||||
Revenues | 786.9 | 168.8 | 390.2 | 677.5 | 999.8 | 360.6 | +113.6 | 596.2 | +52.8 | 821.5 | +21.3 | ||||||||
Sales | 633.3 | 130.3 | 304.1 | 538.7 | 802.8 | 242.7 | +86.3 | 452.8 | +48.9 | 644.7 | +19.7 | ||||||||
Domestic | 409.1 | 94.9 | 203.4 | 362.6 | 518.9 | 161.7 | +70.4 | 273.8 | +34.6 | 387.6 | +6.9 | ||||||||
Overseas | 224.2 | 35.4 | 100.7 | 176.0 | 283.9 | 81.0 | +128.8 | 179.0 | +77.8 | 257.1 | +46.1 | ||||||||
Royalties and other operating income | 153.6 | 38.6 | 86.1 | 138.8 | 196.9 | 25.9 | (32.9) | 51.4 | (40.3) | 84.9 | (38.8) | ||||||||
Royalty and profit-sharing income | 129.6 | 36.6 | 83.3 | 135.4 | 187.2 | 25.2 | (31.1) | 50.4 | (39.5) | 80.7 | (40.4) | ||||||||
Other operating income | 24.1 | 2.0 | 2.8 | 3.4 | 9.8 | 0.7 | (65.0) | 1.0 | (64.3) | 4.2 | +23.5 | ||||||||
Other revenue | - | - | - | - | - | 91.9 | - | 91.9 | - | 91.9 | - | ||||||||
Cost of sales | (273.5) | (55.3) | (123.4) | (227.6) | (338.1) | (114.4) | +106.9 | (194.2) | +57.4 | (263.3) | +15.7 | ||||||||
(% of Sales) | 43.2 | 42.4 | 40.6 | 42.2 | 42.1 | 47.1 | - | 42.9 | - | 40.8 | - | ||||||||
Gross profit | 513.5 | 113.5 | 266.8 | 449.9 | 661.6 | 246.1 | +116.8 | 401.9 | +50.6 | 558.1 | +24.0 | ||||||||
(% of Revenues) | 65.3 | 67.2 | 68.4 | 66.4 | 66.2 | 68.2 | - | 67.4 | - | 67.9 | - | ||||||||
Operating expenses | (212.3) | (49.5) | (106.2) | (167.1) | (239.7) | (59.1) | +19.4 | (115.0) | +8.3 | (174.3) | +4.3 | ||||||||
(% of Revenues) | 27.0 | 29.3 | 27.2 | 24.7 | 24.0 | 16.4 | - | 19.3 | - | 21.2 | - | ||||||||
Marketing and distribution | (72.6) | (15.9) | (33.8) | (52.2) | (76.6) | (16.8) | +5.7 | (35.3) | +4.4 | (54.1) | +3.6 | ||||||||
(% of Revenues) | 9.2 | 9.4 | 8.7 | 7.7 | 7.7 | 4.7 | - | 5.9 | - | 6.6 | - | ||||||||
Research and development | (117.9) | (29.7) | (63.3) | (99.5) | (137.3) | (33.9) | +14.1 | (67.7) | +7.0 | (104.4) | +4.9 | ||||||||
(% of Revenues) | 15.0 | 17.6 | 16.2 | 14.7 | 13.7 | 9.4 | - | 11.4 | - | 12.7 | - | ||||||||
General and administration | (21.8) | (3.9) | (9.1) | (15.3) | (25.8) | (8.5) | +117.9 | (12.0) | +31.9 | (15.8) | +3.3 | ||||||||
(% of Revenues) | 2.8 | 2.3 | 2.3 | 2.3 | 2.6 | 2.4 | - | 2.0 | - | 1.9 | - | ||||||||
Operating profit | 301.2 | 64.0 | 160.7 | 282.8 | 421.9 | 187.0 | +192.2 | 286.9 | +78.5 | 383.8 | +35.7 | ||||||||
(% of Revenues) | 38.3 | 37.9 | 41.2 | 41.7 | 42.2 | 51.9 | - | 48.1 | - | 46.7 | - | ||||||||
Financing costs | (0.1) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | 0.0 | (0.0) | 0.0 | (0.0) | 0.0 | ||||||||
Other financial income (expense) | (1.5) | 0.3 | 0.6 | 0.9 | 0.1 | 1.6 | +433.3 | 2.4 | +300.0 | 0.6 | (33.3) | ||||||||
Other expense | (1.5) | - | (0.0) | (2.8) | (2.5) | (2.4) | - | (2.4) | 0.0 | (2.4) | (14.3) | ||||||||
Profit before taxes | 298.2 | 64.2 | 161.3 | 280.9 | 419.4 | 186.2 | +190.0 | 286.9 | +77.9 | 382.0 | +36.0 | ||||||||
(% of Revenues) | 37.9 | 38.0 | 41.3 | 41.5 | 41.9 | 51.6 | - | 48.1 | - | 46.5 | - | ||||||||
Income taxes | (83.5) | (16.8) | (43.1) | (76.8) | (116.4) | (54.4) | +223.8 | (82.8) | +92.1 | (110.0) | +43.2 | ||||||||
Net income | 214.7 | 47.4 | 118.1 | 204.2 | 303.0 | 131.8 | +178.1 | 204.2 | +72.9 | 272.0 | +33.2 | ||||||||
(% of Revenues) | 27.3 | 28.1 | 30.3 | 30.1 | 30.3 | 36.6 | - | 34.3 | - | 33.1 | - | ||||||||
Attributable to | |||||||||||||||||||
Chugai shareholders | 214.7 | 47.4 | 118.1 | 204.2 | 303.0 | 131.8 | +178.1 | 204.2 | +72.9 | 272.0 | +33.2 | ||||||||
Non-controlling interests | - | - | - | - | - | - | - | - | - | - | - | ||||||||
Earnings per share | |||||||||||||||||||
Basic (yen) | 130.66 | 28.84 | 71.86 | 124.17 | 184.29 | 80.14 | +177.9 | 124.14 | +72.8 | 165.35 | +33.2 | ||||||||
Diluted (yen) | 130.53 | 28.82 | 71.81 | 124.09 | 184.17 | 80.09 | +177.9 | 124.08 | +72.8 | 165.29 | +33.2 |
Other financial income (expense) includes net amount of FX related gains/losses.
Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. "Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on 24 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 October 2022 08:09:09 UTC.